In a recent Wall Street Journal (WSJ) report, Tesla billionaire Elon Musk’s confirmed use of illegal drugs has raised concerns among insiders and the public alike.
The investigation revealed that several current and former executives of SpaceX and Tesla Inc. knew about Musk’s drug use, with concerns about the extent and the fact that he consumed narcotics with board members.
A WSJ investigation revealed that the board did not investigate Musk’s drug use or document any concerns.
The revelation comes as a Delaware court criticized the connection between Musk and his executives, citing a conflict of interest in their decision to declare Musk’s $55 billion compensation package excessive.
Musk, who heads Tesla, SpaceX, X, The Boring Co, Neuralink and xAI, has reportedly used hallucinogenic mushrooms, cocaine, ecstasy and LSD at private parties. Despite these revelations, Musk remains unapologetic.
When asked about the WSJ report, he replied, “Whatever I’m doing, of course I should keep doing it!” Musk highlighted the success of Tesla and SpaceX as the world’s most valuable automotive and space companies, stressing that if drugs improve his productivity, he will take them.
According to the WSJ report, Musk’s close associates and board members believed they had to participate in illegal drug use with him in order not to offend him and risk their social standing in his circle. The report suggested that individuals were careful not to jeopardize the “social capital” associated with being in Musk’s social circle.
Elon Musk’s attorney, Alex Spiro, said Musk underwent random and routine drug tests at SpaceX and passed every one of them. Despite these claims, concerns remain about the implications of Musk’s drug use, particularly in relation to corporate governance and potential conflicts of interest on the boards of SpaceX and Tesla Inc.
As the story continues to unfold, it raises questions about the responsibilities of business leaders and the potential impact of personal decisions on their professional relationships and business decisions. The controversy surrounding Musk’s unapologetic stance on his drug use adds a layer of complexity to ongoing discussions about corporate governance and accountability at major companies.
